Deltagen, Inc. (OTC:DGEN) has announced the financial results for the three months ended September 30, 2009. The company reported revenues of $0.467 million, attributable to license fees for the provision of knockout mice and related phenotypic data for orders placed by customers under Deltagen’s DeltaOne™ program. The company’s interest income was $0.003 million.
MicroCap Insider is a web-based financial portal.
Sign Up for our Free Stock Newsletter
MicroCap Insider publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors.
Deltagen’s total consolidated expenses for the period was $0.582 million, attributable to labor costs and general and administrative expenses. The expenses also include $0.157 million in royalty and commission expenses. They also include a total of $0.128 million for the acquisition of Benten BioServices, Inc.
The full financial report is available online at http://www.deltagen.com/.
Deltagen, Inc. uses in-vivo derived mammalian gene function information to define the function and disease relevance of mammalian genes for the purposes of discovering and validating novel drug targets. The Company's products, based on its platform technology, provide databases of in-vivo mammalian gene function information on target genes of interest to drug researchers. The customers and partners include companies, such as Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc. and Schering-Plough Research Institute, as well as biotechnology and biopharmaceutical companies, including Millennium Pharmaceuticals, Tanox, Inc., Nuvelo, Inc. and Lexicon Genetics Incorporated. In June 2003, the Company filed a voluntary petition for protection under Chapter 11 of the United States Bankruptcy Code. In December 2009, the Company acquired Benten BioServices, Inc.
Sign Up for FREE. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website.
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer.
